Ovulation induction and ovarian malignancy

Seminars in Reproductive Endocrinology

Volumn 14, Issue 4, 1996, Pages 367-374

  Beltsos, Angeline N ^a   Odem, Randall R ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b Department of Obstetrics ^*  (United States)

Author keywords

fertility drugs; ovarian cancer; ovarian hyperstimulation

Indexed keywords

CHORIONIC GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; SERIC GONADOTROPIN; UROFOLLITROPIN;

CANCER RISK; CASTRATION; CLINICAL PRACTICE; FEMALE INFERTILITY; GENETIC PREDISPOSITION; GONADOTROPIN BLOOD LEVEL; HUMAN; OVARY CANCER; OVARY HYPERSTIMULATION; OVARY INSUFFICIENCY; OVULATION INDUCTION; OVULATION INHIBITION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 0030465049     PISSN: 07348630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1067981     Document Type: Review

References (76)

1. Whittemore AS: The risk of ovarian cancer after treatment for infertility (editorial comment). N Engl J Med 331(12):805-806, 1994
2. Wilcox LS, Mosher WD: Use of infertility services in the United States. Obstet Gynecol 82:122-127, 1993
3. Office of Technology Assessment, Congress of the United States. Infertility: Medical and social choices: Summary. Washington, DC: Office of Technology Assessment, 1988. (Publication no. OTA-BA 359S.)
4. Chandra A, Krulewitch CJ, Hoffman HJ: Ovulation drug data from the National Center for Health Statistics. J Womens Health 2:205, 1993 Abstract.
5. Wysowski DK: Use of fertility drugs in the United States, 1973 through 1991. Fertil Steril 60:1096-1098, 1993
6. Whittemore AS: For the Collaborative Ovarian Cancer Group letter-the author's reply (Letter). Am J Epidemiol 137:928-929, 1993
7. Shapiro S: "The author's rely" to "Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 U.S. casecontrol studies. II. Invasive epithelial ovariancancers in white women" (Letter). Am J Epidemiol 140:958, 1994
8. Kotz HL, Herrmann W: A review of the endocrine induction of human ovulation. I-VI. Introduction, Thyroid, Estrogens, Progesterone. Fertil Steril 12:96-107, 196-207, 299-308, 375-394, 1961
9. Cohen J, International Federation of Fertility Societies (IFFS): Fertility drugs and ovarian cancer. Fertil Steril 60:406-408, 1993
10. Berek JS, Hacker NF: Practical Gynecological Oncology. Baltimore, Williams and Wilkins, 1994, p 136
11. Willemson W, Kruitwagen R, Bastiaans B, Haselaar T, Rolland R: Ovarian stimulation and granulosa cell rumour. Lancet 341:986-988, 1993
12. Stouffer RL, Grodin MS, Davis JR, Surwit EA: Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotropin in human ovarian cancers. J Clin Endocrinol Invest 15:441-446, 1992
13. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG: Ovarian tumors in a cohort of infertile women. N Engl J Med 331:771-776, 1994
14. Del Priore, G, Robischon K, Phipps WR: Risk of ovarian cancer after treatment for infertility - Letter. N Engl J Med 332:1300-1302, 1995
15. Teter J, Boczkowski K: Occurence of tumors in dysgenetic gonads. Cancer 20:1301-1310, 1967
16. Scully RE: Neoplasia associated with aomalous sexual development and abnormal sex chromosomes. Pediatr Adolesc Endocrinol 8:203-217, 1981
17. Miller DS, Teng NHT, Ballon SC: Epithelial ovarian carcinoma in patients with intersex disorders: The role of pituitary gonadotropins in ovarian tumorigenesis. Gynecol Oncol 24:299-308, 1986
18. Dinnerstein AJ, O'Leary JA: Granulosa-theca cell tumors: A clinical review of 102 patients. Obstet Gynecol 31:654-658, 1986
19. Kolstad P, Beecham JB: Epidemiology of ovarian neoplasia. In de Watterville H (ed): Diagnosis and Treatment of Ovarian Neoplastic Alterations. Amsterdam, Excerpta Medica, 1975, p 56
20. Laohn RE, Buger HG, Bouma J, et al: Inhibin as a marker for granulosa cell tumors. N Engl J Med 321:826, 1989
21. McGowan L, Davis RH: Intrasplenic ovarian grafts in Syrian hamsters and peritoneal fluid cellular distribution (34823). Proc Soc Exp Biol Med 134:507-509, 1970
22. Shirama K, Hokano M: Ultrastructural study on experimentally induced ovarian tumors in the rat. J Endocrinol Invest 15:417-422, 1992
23. Biskind GR, Bernstein DE, Gospe SM: The effect of exogenous gonadotropins on the development of experimental ovarian rumors in rats. Cancer Res 13:216-221, 1953
24. Biskind GR, Biskind MS: Atrophy of ovaries transplanted to the spleen in unilaterally castrated rats: Proliferative changes following subsequent removal of intact ovary. Science 108:137-138, 1948
25. Horn-Ross PL, Whittemore AS, Harris R, Itnyre J, Collaborative Ovarian Cancer Group: Characteristics relating to ovarian cancer risk: Collaborative analysis of twelve United States case-control studies: VI. nonepithelial cancers among adults. Epidemiology 3:490-495, 1992
26. Fathalla MF: Incessant ovulation - A factor in ovarian neoplasia? Lancet 2:163, 1971
27. Rao AR: Effects of carcinogen and/or mutagen on normal and gonadotropin-primed ovaries of mice. Int J Cancer 28:105-110, 1981
28. Richards JS: Hormonal control of follicular growth and maturation in mammals. In Jones RE (ed): The Vertebrate Ovary. New York, Plenum Press, 1978, p 331
29. Fishel S, Jackson P: Follicular stimulation for high tech pregnancies: Are we playing it safe? Br Med J 299:309-311, 1989
30. Biskind MS, Biskind GS: Devlopment of tumors in the rat ovary after transplantation into the spleen. Proc Soc Exp Biol Med 55:176-179, 1944
31. Li MH, Gardner WU: Further studies on the pathogenesis of ovarian tumors in mice. Cancer Res 9:35-41, 1949
32. Michael SD, Taguchi O, Nishizuka Y: Changes in hypophyseal hormones associated with accelerated aging and tumorigenesis of the ovaries in neonatally thymectomized mice. Endocrinology 108:2375-2379, 1981
33. Davy M, Torjesen PA, Aakvaag A: Demonstration of an FSH receptor in a functioning granulos tumor. Acta Endocrinol. (Copenh) 85:615-623, 1977
34. Simon WE, Holzel F: Hormone sensitivity of gynecological tumor cells in tissue culture. J Cancer Res Clin Oncol 93:307-323, 1979
35. Simon WE, Albrecht M, Hansel M, Dietel M, Holzel F: Cell lines derived from human ovarian carcinomas: Growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 70:839-845, 1983
36. Quinn MA, Baker HWG, Rome R, Fortune D, Brown JB: Response of a mucinous ovarian tumor of borderline malignancy to human chorionic gonadotropin. Obstet Gynecol 61:121-126, 1983
37. Wardlaw S, Lauersen NH, Saxena BB: The LH-hCG receptor of human ovary at various stages of the menstrual cycle. Acta Endocrinol (Copenh) 79:568-576, 1975
38. Bohnet HG: Determination and properties of proteohormone receptors in malignant gynceological tumors with special reference to lactogen receptors in human breast cancer. Arch Gynecol 229:333-344, 1980
39. Wilson SJ, Young BK, Katz M, Kammerman S, Epstein J, Bigelow B: A gonadotropin-responsive virilizing granulosa tumor. Diag Gynecol Obstet 2:275-281, 1980
40. Ranjaniemi H, Kauppila A, Rounber L, Selander K, Pystynen P: LH (hCG) receptor in benign and malignant tumors of human ovary. Acta Obstet Gynecol Scand 101(Suppl):83-86, 1981
41. Kammerman S, Demopoulos RI, Raphael C, Ross J: Gonadotropic hormone binding to human ovarian tumors. Hum Pathol 12:886-890, 1981
42. Lynch HT, Conway T, Lynch J: Hereditary ovarian cancer. In Sharp F, Mason WP, Leake RE (eds): Ovarian Cancer: Biological and Therapeutic Changes. Cambridge, Chapman and Hall Medical, 1990, p 719
43. McDonough PG: Editor's comments. Fertil Steril 60:200-201, 1993
44. Ben-Hur H, Dgari R, Lancet M, Katz Z, Nissim F, Rosenman D: Ovarian carcinoma masquerading as ovarian hyperstimulation syndrome. ACTA Ostet Gynecol Scan 65:813-814, 1986
45. Atlas M, Menczer J: Massive hyperstimulation and borderline carcinoma of the ovary, a possible association. ACTA Obstet Gynecol Scand 61:261-263, 1982
46. Spirtas R, Kaufman SC, Alexander NJ: Ferility drugs and ovarian cancer: Red alert or red herring? Fertil Steril 59:291-293, 1993
47. Derder MC: Fertility drugs and ovarian cancer: Red alert or red herring - new information (letter to editor). Fertil Steril 60:199-200, 1993
48. Spirtas R, Kaufman S, Alexander NJ: Drugs and ovarian cancer: Red alert or red herring - new information (letter to editor). Fertil Steril 60:199-200, 1993
49. Kulkaris R, McGarry JM: Follicular stimulation and ovarian cancer (letter). Brit Med J 299:740, 1989
50. Diett J: Ovulation and ovarian cancer (letter). Lancet 338:445, 1991
51. Hankinson SE, Hunter DJ, Colditz GA, Willet WC, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE: Tubal litigation, hysterectomy, and risk of ovarian cancer. JAMA 249:1596, 1983
52. Centers for Disease Control Cancer and Steroid Hormone Study: Oral Contraceptives and the Risk of Ovarian Cancer. JAMA 249:1596, 1983
53. Whittemore AS, Harris R, Itnyre J, Collaborative Ovarian Cancer Group: Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 136:1184-1203, 1992
54. Harris R, Whittemore AS, Itnyre J, Collaborative Ovarian Cancer Group: Characteristics relating to ovarian cancer risk: Collaborative analysis of twelve US case-control studies. III. Epithelial tumors of low malignant potential in white women. Am J Epidemiol 136:1204-1211, 1992
55. Hartge P, Schiffman MH, Hoover R, McGowan L, Lesher L, Norris HJ: A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol 161:10-16, 1989
56. Nasca PC, Greenwald P, Chorost S, Richart R, Caputo T: An epidemiologic case-control study of ovarian cancer and reproductive factors. Am J Epidemiol 119:705-713, 1984
57. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ: Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 71:711-716, 1983
58. Walters DE: Ovarian cancer and pregnancy: Comment on a paper by Whittemore et al. Fertil Steril 61:239-242, 1994
59. Kurman R, Wallach EE, Zacur HA: Letter to Editor. N Engl J Med 332:1301, 1995
60. Cramer DW, Hartge P, Nasca P, Whittemore AS: Letter to editor. New Engl J Med 332:1302, 1995
61. Booth M, Beral V, Smith P: Risk factors for ovarian cancer: A case-control study. Br J Cancer 60:592-598, 1989
62. Lappohn RE, Burger HG, Bouma J, Bangah M, Krans M, de Bruyn HWA: Inhibin as a marker for granulosa-cell tumors. New Engl J Med 321:790-793, 1989
63. Jansen R: Ovarian stimulation and granulosa-cell tumour (letter). Lancet 341:1345, 1993
64. Evers J: Ovarian stimulation and granulosa-cell tumour (letter). Lancet 341:1345, 1993
65. Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG: Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 65:13-18, 1996
66. Ron E, Lunenfeld B, Menczer J, Blumstein T, Katz L, Oelsner G, Serr D: Cancer incidence in a cohort of infertile women. Am J of Epidem 125:780-790, 1987
67. Venn A, Watson L, Lumley J, Giles G, King C, Healy D: Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 346:995-1000, 1995
68. Fertility drugs and the risk of ovarian and breast cancer. Bethesda, MD; National Institute of Health, 1994. (NICHD Contract No., 1-MD-4-3210, 1994 and RO1 HD 32175, 1996).
69. RFP: Cancer risk following evaluation and treatment for infertility. Bethesda, MD: N 14, 1993 (NCI-CP-40511-21).
70. Ovarian risk and hypergonadotrophic therapy. Bethesda, MD: National Institute of Health, (5 RO1 CA54419-04), 1995
71. Collaborative study of ovarian cancer in two riskgroups. Bethesda, MD: National Institute of Health (5 RO1 CA58598-03), 1995
72. Epidemiology of epithelial ovarian cancer. Bethesda, MD: National Institute of Health (5RO1 CA61093-03), 1995
73. Risk factors and prognostic factors for ovarian cancer. Bethesda, MD: National Institute of Health (5RO1 CA 61107-03), 1995
74. Epidemiology of ovarian cancer. Bethesda, MD: National Institute of Health (5 RO1 CA61126-03), 1995
75. NIH Consensus on Ovarian Cancer: Screening, treatment, and follow-up. National Institute of Health Consensus Statement 507, 12 (3), April 1994
76. Reynolds T: Fertility drugs may raise ovarian cancer risk. J of NCI 85:84-86, 1993